Picture of Prophase Labs logo

PRPH Prophase Labs News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Prophase Labs Inc reports results for the quarter ended in December - Earnings Summary

* Prophase Labs Inc  PRPH.OQ  reported a quarterly adjusted
loss
of 51 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -12 cents.  The mean expectation of two analysts for the
quarter was for a loss of 26 cents per share. Wall Street
expected results to range from -27 cents to -25 cents per share.
    * Revenue fell 80.1% to $4.35 million from a year ago;
analysts
expected $10.69 million. 
    * Prophase Labs Inc's reported EPS for the quarter was a
loss
of 51 cents​.
    * The company reported a quarterly loss of $8.75 million.
    * Prophase Labs Inc shares had risen by 7.5% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Prophase
Labs Inc
is $15.50 

This summary was machine generated from LSEG data March 15 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.26          -0.51          Missed
 Sep. 30 2023      -0.19          -0.30          Missed
 Jun. 30 2023      -0.14          -0.20          Missed
 Mar. 31 2023      -0.10          0.03           Beat

Recent news on Prophase Labs

See all news